The real benefits of taking semaglutide — and what the evidence actually shows

The biggest misconception: semaglutide is just an appetite suppressant

A lot of people come to semaglutide expecting something like a stronger version of the diet pills they've seen advertised over the years. That framing undersells what's happening physiologically. Semaglutide is a GLP-1 receptor agonist, it mimics a gut hormone that the body already produces after eating. When you inject it once a week, it signals the brain that you're full, slows the rate at which food leaves the stomach, and reduces the drive to eat between meals. The result isn't white-knuckling through hunger; it's a genuine reduction in appetite that many people describe as the first time food hasn't dominated their thinking. That's a meaningful distinction.

The clinical trial evidence is specific. In STEP 1, published in the New England Journal of Medicine, adults without diabetes taking semaglutide 2.4mg lost an average of around 15% of their body weight over 68 weeks, compared with about 2.4% in the placebo group. Participants also saw reductions in waist circumference, blood pressure and fasting blood glucose, improvements that matter clinically, not just cosmetically. The weight-loss-specific benefits of semaglutide are documented across thousands of trial participants, which is why NICE has recommended it for eligible adults.

So the misconception isn't that semaglutide works, it does. The misconception is that it works in a simple or superficial way. It intervenes at the level of hormonal signalling. That's why it needs clinical assessment, and why the dose is titrated gradually rather than started at full strength.

What the benefits of Wegovy look like in practice

Beyond the headline weight figure, the benefits of taking Wegovy spread into everyday life in ways trials can partially quantify but patients often describe better. Physical load reduces: joints, blood pressure, and the cardiovascular system all carry less strain as weight falls. Blood sugar levels tend to improve even in people who don't have diabetes, which matters for long-term metabolic health. Many people report that their energy levels stabilise as the appetite-signalling noise quiets down.

There are also benefits that sit outside the purely physical. Reduced weight can improve sleep quality, particularly in people with mild obstructive sleep apnoea. Mood and confidence often shift, though these are harder to attribute directly. The NHS notes that losing even 5–10% of body weight can reduce the risk of developing type 2 diabetes and improve existing conditions like high blood pressure, and semaglutide consistently achieves multiples of that in trials.

For people weighing up their options, the cost of Wegovy is a practical consideration alongside these clinical outcomes. It's worth thinking about both together. A fuller picture of what semaglutide is and how it's used is on our semaglutide overview page if you'd like the wider context before deciding anything.

One thing worth knowing: the benefits of Wegovy are tied to continued use. Weight management medicines work while they're being taken, and the evidence base reflects sustained treatment, not a short course. That's a conversation for a prescriber, not something to assume either way.

Who tends to see the greatest benefit, and what eligibility looks like

NICE recommends semaglutide (TA875) for adults with a BMI of 35 or above and at least one weight-related condition, used within a specialist weight management service for a maximum of two years. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. The private licensed eligibility is somewhat broader: adults with a BMI of 30 or above, or 27 or above alongside a relevant condition such as high blood pressure, raised cholesterol, prediabetes or obstructive sleep apnoea, may be considered. But BMI alone isn't the whole picture, the prescriber looks at your health history, current medicines and individual circumstances before any treatment is issued.

People sometimes ask whether the benefits differ by starting weight. The percentage reductions in trials are fairly consistent across BMI bands, though the absolute amount lost naturally varies with starting weight. What does seem to influence outcomes is consistency: taking the weekly injection at a regular time, following the titration schedule, and pairing treatment with the dietary and activity changes the licence recommends. Our page on timing your Wegovy dose covers the practical side of that in more detail.

For those wondering about hair changes during treatment, it's a question our clinical team hears regularly, not everyone loses hair on Wegovy, and the page explains what's actually known. If you'd rather read about the broader role of nutritional support alongside semaglutide, that's covered too. The NHS has a patient-level overview of semaglutide including its common side effects, which is worth reading alongside anything you find here.

Side effects: honest about the trade-offs

The benefits of semaglutide are well evidenced, but they come with a side-effect profile that deserves honest treatment rather than a footnote. The most common effects are gastrointestinal: nausea, loose stools, constipation, indigestion and occasional vomiting. These are most noticeable in the first few weeks after starting or after a dose increase, and they settle for most people as the body adjusts. Starting at a low dose and increasing gradually is how the titration schedule is designed, to let the system adapt.

Less common but more serious: pancreatitis has been identified as an infrequent but known risk with GLP-1 medicines. Severe, persistent stomach pain that radiates to the back, with or without vomiting, warrants urgent medical attention. The MHRA flagged this in a Drug Safety Update in January 2026. Gallbladder issues are also worth knowing about, particularly in people with a history of gallstones.

Semaglutide is not recommended during pregnancy, while breastfeeding, or for anyone trying to conceive. It's not licensed for under-18s. Anyone with a history of certain thyroid conditions or pancreatitis should raise those details during a clinical assessment. These aren't reasons to avoid the conversation, they're exactly what a proper consultation is for.

If you'd like to explore treatment options with a prescriber, you can start a free consultation with nume, a real clinician, not an automated system, reads your application the same day.